Welcome!

News Feed Item

Oncolytics Biotech® Inc. Announces Second Quarter 2014 Results

CALGARY, Aug. 7, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the second quarter ended June 30, 2014.

"Our randomized clinical program continued to advance during the quarter as we recently reported the completion of enrollment in a Phase II study using REOLYSIN® in combination with carboplatin and paclitaxel in pancreatic cancer patients," said Dr. Brad Thompson, President and CEO of Oncolytics. "We also strengthened our board, adding two directors with significant financial and public company experience."

Selected Highlights

Since April 1, 2014, selected highlights announced by the Company include:

Clinical and Preclinical Data

  • Completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045);
  • Early results from a translational study looking at intravenous administration of REOLYSIN® to patients with primary or metastatic brain tumors was presented at the ASCO Annual Meeting in Chicago, IL;
  • Final data from the Company's randomized, double-blinded clinical study examining REOLYSIN® in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers;
  • A series of presentations by research collaborators at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK covering:
    • early clinical research showing that intravenously delivered REOLYSIN® can cross the blood brain barrier to access tumours in the brains of humans;
    • preclinical research examining the synergies associated with treatment in animal models with GM-CSF prior to administering REOLYSIN®;
    • preclinical research focused on identifying biomarkers predictive of sensitivity/resistance to reovirus in head and neck cancer cell lines; and
    • preclinical research into the treatment of hepatocellular carcinoma associated with infection by Hepatitis B and Hepatitis C.

Governance

  • The nomination and election of Ms. Linda Hohol and Ms. Angela Holtham to the Company's board of directors; and

Financial

  • At June 30, 2014 the Company reported $18.9 million in cash, cash equivalents and short-term investments.

 



ONCOLYTICS BIOTECH INC.
INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(unaudited)






June 30,

2014

$


December 31,

2013

$

Assets




Current assets




Cash and cash equivalents

16,880,730


25,220,328

Short-term investments

2,031,685


2,001,644

Accounts receivable

54,391


105,853

Prepaid expenses

609,538


361,743

Total current assets

19,576,344


27,689,568





Non-current assets




Property and equipment

470,217


532,459

Total non-current assets

470,217


532,459





Total assets

20,046,561


28,222,027





Liabilities And Shareholders' Equity




Current Liabilities




Accounts payable and accrued liabilities

3,667,076


6,008,661

Total current liabilities

3,667,076


6,008,661





Shareholders' equity








Share capital
  Authorized: unlimited   Issued:




   June 30, 2014 – 87,537,397




   December 31, 2013 – 84,803,818

232,303,714


228,612,564

Warrants


376,892

Contributed surplus

25,538,706


24,491,212

Accumulated other comprehensive loss

87,679


79,698

Accumulated deficit

(241,550,614)


(231,347,000)

Total shareholders' equity

16,379,485


22,213,366

Total liabilities and equity

20,046,561


28,222,027

 

 


ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(unaudited)










Three Month
Period
Ending June
30, 2014
$


Three Month
Period
Ending June
30, 2013
$


Six Month
Period
Ending June
30, 2014
$


Six Month
Period
Ending June
30, 2013
$









Expenses








  Research and development

3,555,055


3,804,307


7,733,389


8,921,351

  Operating

1,209,815


1,320,742


2,601,069


2,885,493

Operating loss

(4,764,870)


(5,125,049)


(10,334,458)


(11,806,844)

  Interest

50,253


105,368


138,240


180,327

Loss before income taxes

(4,714,617)


(5,019,681)


(10,196,218)


(11,626,517)

 Income tax expense

(3,546)



(7,396)


Net loss

(4,718,163)


(5,019,681)


(10,203,614)


(11,626,517)

Other comprehensive income items that may be

  reclassified to net loss
















Translation adjustment

26,675


73,451


7,981


107,639









Net comprehensive loss

(4,691,488)


(4,946,230)


(10,195,633)


(11,518,878)

Basic and diluted loss per common share

(0.05)


(0.06)


(0.12)


(0.14)

Weighted average number of shares
(basic and diluted)

86,581,854


84,758,818


85,869,008


82,276,330









  

 


ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(unaudited)














Share Capital

$


Contributed
Surplus

$


Warrants

$


Accumulated
Other
Comprehensive
Loss

$


Accumulated
Deficit

$


Total

$

As at December 31, 2012

198,155,091


24,126,265


376,892


(57,115)


(207,814,353)


14,786,780













Net loss and
comprehensive loss




107,639


(11,626,517)


(11,518,878)

Issued, pursuant to a
bought deal financing

30,218,797






30,218,797

Exercise of stock options

139,676


(34,687)





104,989













Share based compensation


250,853





250,853

As at June 30, 2013

228,513,564


24,342,431


376,892


50,524


(219,440,870)


33,842,541














Share Capital

$


Contributed
Surplus

$


Warrants

$


Accumulated
Other
Comprehensive
Loss

$


Accumulated
Deficit

$


Total

$













As at December 31, 2013

228,612,564


24,491,212


376,892


79,698


(231,347,000)


22,213,366













Net loss and
comprehensive loss




7,981


(10,203,614)


(10,195,633)

Issued, pursuant to Share
Purchase Agreement

3,691,150






3,691,150

Expired warrants


376,892


(376,892)
















Share based compensation


670,602





670,602

As at June 30, 2014

232,303,714


25,538,706



87,679


(241,550,614)


16,379,485

 

 

 


ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)










Three Month
Period
Ending June
30, 2014

$


Three Month
Period
Ending June
30, 2013

$


Six Month
Period
Ending June
30, 2014

$


Six Month
Period
Ending June
30, 2013

$









Operating Activities








Net loss for the period

(4,718,163)


(5,019,681)


(10,203,614)


(11,626,517)

  Amortization - property and equipment

38,512


25,565


78,169


50,146

  Share based compensation

366,005


129,997


670,602


250,853

  Unrealized foreign exchange loss

(74,059)


209,804


(49,989)


(97,849)

Net change in non-cash working capital

(1,392,530)


(455,283)


(2,439,481)


(2,096,453)

Cash used in operating activities

(5,780,235)


(5,109,598)


(11,944,313)


(13,519,820)

Investing Activities








Acquisition of property and equipment

(1,239)


(132,164)


(17,219)


(147,302)

Purchase of short-term investments



(30,041)


(32,416)

Cash used in investing activities

(1,239)


(132,164)


(47,260)


(179,718)

Financing Activities








Proceeds from exercise of stock options and

  warrants




104,989

Proceeds from Share Purchase Agreement

2,502,708



3,691,150


Proceeds from public offering


11,735



30,218,797

Cash provided by financing activities

2,502,708


11,735


3,691,150


30,323,786

Increase in cash

(3,278,766)


(5,230,027)


(8,300,423)


16,624,248

Cash and cash equivalents, beginning of period

20,155,907


41,519,657


25,220,328


19,323,541

Impact of foreign exchange on cash and cash

  equivalents

3,589


(136,353)


(39,175)


205,488

Cash and cash equivalents, end of period

16,880,730


36,153,277


16,880,730


36,153,277

 

To view the Company's Second Quarter 2014 Consolidated Financial Statements, related Notes to Consolidated Financial Statements, and Management's Discussion and Analysis, please see the Company's quarterly filings which will be available on www.sedar.com and on www.oncolyticsbiotech.com/for-investors/financials.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2014 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Many private cloud projects were built to deliver self-service access to development and test resources. While those clouds delivered faster access to resources, they lacked visibility, control and security needed for production deployments. In their session at 18th Cloud Expo, Steve Anderson, Product Manager at BMC Software, and Rick Lefort, Principal Technical Marketing Consultant at BMC Software, discussed how a cloud designed for production operations not only helps accelerate developer in...
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Ask someone to architect an Internet of Things (IoT) solution and you are guaranteed to see a reference to the cloud. This would lead you to believe that IoT requires the cloud to exist. However, there are many IoT use cases where the cloud is not feasible or desirable. In his session at @ThingsExpo, Dave McCarthy, Director of Products at Bsquare Corporation, will discuss the strategies that exist to extend intelligence directly to IoT devices and sensors, freeing them from the constraints of ...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Venafi has extended the power of its platform in an easy-to-use utility for DevOps teams available for immediate download. Now DevOps teams can eliminate the hassle of acquiring and installing TLS keys and certificates. Instead, customers can focus on speeding up continuous development and deployment, while security teams have complete visibility and can keep the DevOps environment secure and compliant to protect customer data. Extending the Venafi Trust Protection Platform requires only a singl...
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
The competitive landscape of the global cloud computing market in the healthcare industry is crowded due to the presence of a large number of players. The large number of participants has led to the fragmented nature of the market. Some of the major players operating in the global cloud computing market in the healthcare industry are Cisco Systems Inc., Carestream Health Inc., Carecloud Corp., AGFA Healthcare, IBM Corp., Cleardata Networks, Merge Healthcare Inc., Microsoft Corp., Intel Corp., an...
The best-practices for building IoT applications with Go Code that attendees can use to build their own IoT applications. In his session at @ThingsExpo, Indraneel Mitra, Senior Solutions Architect & Technology Evangelist at Cognizant, provided valuable information and resources for both novice and experienced developers on how to get started with IoT and Golang in a day. He also provided information on how to use Intel Arduino Kit, Go Robotics API and AWS IoT stack to build an application tha...
Is your aging software platform suffering from technical debt while the market changes and demands new solutions at a faster clip? It’s a bold move, but you might consider walking away from your core platform and starting fresh. ReadyTalk did exactly that. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue and over a decade of audio conferencing product development to start an innovati...
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, discussed the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filterin...
Cloud analytics is dramatically altering business intelligence. Some businesses will capitalize on these promising new technologies and gain key insights that’ll help them gain competitive advantage. And others won’t. Whether you’re a business leader, an IT manager, or an analyst, we want to help you and the people you need to influence with a free copy of “Cloud Analytics for Dummies,” the essential guide to this explosive new space for business intelligence.
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, provided tips on how to be successful in large scale machine learning...
Early adopters of IoT viewed it mainly as a different term for machine-to-machine connectivity or M2M. This is understandable since a prerequisite for any IoT solution is the ability to collect and aggregate device data, which is most often presented in a dashboard. The problem is that viewing data in a dashboard requires a human to interpret the results and take manual action, which doesn’t scale to the needs of IoT.
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...